Table 4.
Median overall survival and univariable analysis of prognostic factors for overall survival for all patients and divided by biological subtype
| Number of events/patients | Median OS, months (95% CI) | Log rank p-value | Hazard Ratio (95% CI) | Wald p-value | |
|---|---|---|---|---|---|
| All patients | 408/439 | 8.6 (7.4–9.8) | < 0.001 | ||
| ER + /HER2- | 255/279 | 9.5 (8.3–11.1) | Ref. | ||
| HER + | 64/68 | 9.2 (6.9–13.0) | 1.08 (0.82–1.42) | 0.60 | |
| TNBC | 89/92 | 5.4 (4.6–6.6) | 1.66 (1.30–2.13) | < 0.001 | |
| All patients | |||||
| DRFi, years | |||||
| 1st tertile (≤ 4.3) | 113/122 | 6.4 (5.8–9.2) | 0.20 | Ref. | |
| 2nd tertile (> 4.3–8.8) | 115/121 | 10.0 (8.5–13.5) | 0.84 (0.64–1.09) | 0.18 | |
| 3rd tertile (> 8.8) | 108/121 | 9.4 (7.3–12.6) | 0.78 (0.59–1.01) | 0.060 | |
| De novo metastatic | 72/75 | 8.2 (6.1–10.4) | 0.98 (0.73–1.32) | 0.88 | |
| Linear | 0.99 (0.97–1.01) | 0.21 | |||
| Previous chemotherapy lines, n | |||||
| ≤ 2 | 250/274 | 8.8 (7.3–10.7) | 0.065 | Ref. | |
| > 2 | 158/165 | 8.2 (6.4–9.7) | 1.21 (0.99–1.48) | 0.065 | |
| Linear | 1.02 (0.94–1.11) | 0.64 | |||
| ADPT, months | |||||
| 1st tertile (≤ 6.5) | 138/146 | 6.3 (5.4–7.3) | 0.002 | Ref. | |
| 2nd tertile (> 6.5–10.4) | 137/145 | 9.2 (7.7–10.9) | 0.80 (0.63–1.01) | 0.061 | |
| 3rd tertile (> 10.4) | 131/145 | 11.6 (9.4–14.5) | 0.64 (0.51–0.82) | < 0.001 | |
| Linear | 0.96 (0.94–0.98) | < 0.001 | |||
| ER + /HER- | |||||
| DRFi, years | |||||
| 1st tertile (≤ 4.3) | 68/78 | 10.2 (8.3–11.6) | 0.44 | Ref. | |
| 2nd tertile (> 4.3–8.8) | 73/77 | 10.4 (7.3–15.3) | 0.96 (0.69–1.34) | 0.83 | |
| 3rd tertile (> 8.8) | 70/77 | 9.5 (7.1–13.4) | 1.14 (0.81–1.60) | 0.45 | |
| De novo metastatic | 44/47 | 7.9 (5.9–13.9) | 1.28 (0.87–1.87) | 0.21 | |
| Linear | 1.00 (0.98–1.02) | 0.80 | |||
| Previous chemotherapy lines, n | |||||
| ≤ 2 | 156/175 | 10.2 (8.2–12.3) | 0.14 | Ref. | |
| > 2 | 99/104 | 8.7 (7.0–11.4) | 1.21 (0.94–1.56) | 0.14 | |
| Linear | 1.02 (0.92–1.13) | 0.70 | |||
| ADPT, months | |||||
| 1st tertile (≤ 6.5) | 87/93 | 7.9 (6.8–10.6) | 0.14 | Ref. | |
| 2nd tertile (> 6.5–10.4) | 85/92 | 10.6 (8.5–13.5) | 0.81 (0.60–1.10) | 0.17 | |
| 3rd tertile (> 10.4) | 81/92 | 10.7 (7.5–14.8) | 0.76 (0.56–1.04) | 0.083 | |
| Linear | 0.98 (0.95–1.00) | 0.042 | |||
| HER2 + | |||||
| DRFi, years | |||||
| 1st tertile (≤ 2.4) | 15/18 | 6.1 (4.4–46.5) | 0.99 | Ref. | |
| 2nd tertile (> 2.4–4.9) | 17/17 | 10.1 (6.9 –18.3) | 1.05 (0.50–2.19) | 0.89 | |
| 3rd tertile (> 4.9) | 17/18 | 9.3 (5.7 –18.5) | 1.03 (0.49–2.14) | 0.93 | |
| De novo metastatic | 15/15 | 9.8 (6.8–15.7) | 1.12 (0.53–2.36) | 0.77 | |
| Linear | 0.98 (0.92–1.02) | 0.25 | |||
| Previous chemotherapy lines, n | |||||
| ≤ 2 | 30/32 | 10.1 (6.9–16.4) | 0.11 | Ref. | |
| > 2 | 34/36 | 8.5 (5.5–10.7) | 1.53 (0.99–2.59) | 0.11 | |
| Linear | 1.09 (0.90–1.31) | 0.38 | |||
| ADPT, months | |||||
| 1st tertile (≤ 7.8) | 21/23 | 4.4 (3.5–10.2) | 0.16 | Ref. | |
| 2nd tertile (> 7.8–12.4) | 21/22 | 9.3 (6.9–16.9) | 0.65 (0.35–1.20) | 0.16 | |
| 3rd tertile (> 12.4) | 22/23 | 13.7 (8.7–16.5) | 0.56 (0.31–1.04) | 0.064 | |
| Linear | 0.97 (0.92–1.02) | 0.25 | |||
| TNBC | |||||
| DRFi, years | |||||
| 1st tertile (≤ 1.4) | 25/27 | 4.4 (2.4–6.6) | 0.36 | Ref. | |
| 2nd tertile (> 1.4–2.8) | 26/27 | 5.6 (3.9–9.6) | 0.83 (0.47 –1.46) | 0.52 | |
| 3rd tertile (> 2.8) | 25/26 | 8.9 (4.9–15.6) | 0.61 (0.34–1.07) | 0.085 | |
| De novo metastatic | 13/13 | 6.4 (3.4–*) | 0.72 (0.36–1.41) | 0.34 | |
| Linear | 0.99 (0.92–1.06) | 0.75 | |||
| Previous chemotherapy lines, n | |||||
| ≤ 2 | 64/67 | 6.2 (4.9–9.2) | 0.72 | Ref. | |
| > 2 | 25/25 | 4.6 (3.9–9.6) | 1.09 (0.68–1.75) | 0.72 | |
| Linear | 1.01 (0.82–1.26) | 0.89 | |||
| ADPT, months | |||||
| 1st tertile (≤ 5.0) | 31/31 | 4.3 (2.5–5.4) | 0.004 | Ref. | |
| 2nd tertile (> 5.0–8.7) | 30/30 | 6.3 (3.9–9.0) | 0.81 (0.48–1.36) | 0.43 | |
| 3rd tertile (> 8.7) | 28/30 | 12.1 (6.5–15.9) | 0.42 (0.25–0.71) | 0.001 | |
| Linear | 0.93 (0.88–0.97) | 0.002 |
ADPT average duration of previous treatment lines, DRFi distant recurrence-free interval, PFS progression-free survival